news
MHRA approves Epidyolex® (cannabidiol) for TSC seizure treatment
GW Pharmaceuticals received approval for Epidyolex®(cannabidiol) for the treatment of seizures linked to tuberous sclerosis complex (TSC) in the UK.
List view / Grid view
Dosage
news
Monoclonal antibody prevents malaria in small NIH trial
One dose of a monoclonal antibody developed at the US National Institutes of Health (NIH) prevented malaria for up to nine months.
news
Libtayo® with chemotherapy trial stopped early due to success
Phase III trial of Libtayo® (cemiplimab) combined with chemotherapy stops early due to significant improvement in overall survival in lung cancer patients.
news
Remetinostat shows promise as a BCC treatment in Phase II study
Remetinostat, a first-in-class histone deacetylase inhibitor gel, displayed signs of clinical efficacy in patients with basal cell carcinoma.
news
Ritlecitinib improves scalp hair regrowth in alopecia trial
Ritlecitinib was shown to reduce scalp hair loss to less than or equal to 20 percent after six months in Pfizer’s Phase IIb/III trial.
news
Blood thinners reduce need for organ support in COVID-19 patients
Clinical trial shows that treating moderately ill COVID-19 patients with a full-dose blood thinner reduced their need for organ support.
news
Biogen announces results from Phase IIIb NOVA study for MS
Results from the NOVA study show every six-week dosing with natalizumab is as effective as every four-week in relapsing-remitting MS.
news
FDA approves emergency use of REGEN-COVTM for COVID-19 prevention
The FDA have authorised REGEN-COV monoclonal antibody therapy for emergency use as prevention for COVID-19 in certain patients.
news
Salbutamol significantly increases cerebral perfusion in proof-of-concept trial
In the Phase I trial, the beta-2 adrenoceptor agonist salbutamol significantly increased cerebral perfusion, a key biomarker in neurodegenerative disease.
![Lines of vials labelled 'COVID-19 Vaccines' [Credit: Dimitris Barletis/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Covid-19-vaccines-2-1-300x278.jpg)
![Lines of vials labelled 'COVID-19 Vaccines' [Credit: Dimitris Barletis/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Covid-19-vaccines-2-1-e1614176959561.jpg)
news
A single vaccine dose is sufficient for immunity in COVID-19 survivors, finds study
New research shows a second COVID-19 vaccine dose may be unnecessary in individuals previously infected with SARS-CoV-2 and needlessly exposes individuals to higher rates of adverse effects.
![Vial labelled heparin. [Credit: SamaraHeisz5 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Heparin-300x278.jpg)
![Vial labelled heparin. [Credit: SamaraHeisz5 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Heparin-scaled.jpg)
news
Increased heparin dose reduces need for life support in hospitalised COVID-19 patients
Interim data from 1,000 hospitalised patients with moderate COVID-19 symptoms shows that full doses of heparin can improve patient outcomes and could reduce ICU burden.
news
Majority of CMO-acquired dose manufacturing facilities in Europe, report says
A new report has found that three quarters of dose manufacturing facilities acquired by dedicated CMOs in 2019 were in Europe.
article
Patient adherence: the true costs
Adherence to medicines – ie, maintaining consistency and complying with correct dosage – is vital for treatment success, yet patient non-adherence remains a global concern, risking a multitude of consequences for both the patients and healthcare systems. Dave Elder explores the issue of medicine adherence and expounds on current efforts…
news
Gilead announces primary endpoints met in Phase III remdesivir trial
Gilead has said that topline results for clinical recovery have been demonstrated in a Phase III trial of remdesivir, tested in COVID-19 patients.
